HC Wainwright Raises Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at HC Wainwright increased their FY2025 EPS estimates for shares of TG Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will post earnings per share of $1.39 for the year, up from their prior forecast of $1.26. HC Wainwright has a "Buy" rating and a $55.00 price target on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics' FY2026 earnings at $2.27 EPS and FY2027 earnings at $2.86 EPS.

TGTX has been the subject of a number of other reports. JPMorgan Chase & Co. raised their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

Remove Ads

TG Therapeutics Stock Performance

TGTX stock traded up $3.25 during trading on Wednesday, reaching $38.44. The company had a trading volume of 4,137,139 shares, compared to its average volume of 2,560,778. TG Therapeutics has a twelve month low of $12.93 and a twelve month high of $38.58. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market cap of $6.04 billion, a price-to-earnings ratio of -384.36 and a beta of 2.30. The firm has a 50-day simple moving average of $31.07 and a 200-day simple moving average of $28.55.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TGTX. State Street Corp grew its stake in TG Therapeutics by 35.8% in the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock valued at $212,712,000 after acquiring an additional 2,398,015 shares during the period. Clearbridge Investments LLC acquired a new stake in TG Therapeutics during the 4th quarter worth $55,237,000. Principal Financial Group Inc. boosted its stake in TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock worth $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in TG Therapeutics during the 4th quarter worth $14,508,000. Finally, Braun Stacey Associates Inc. acquired a new stake in TG Therapeutics during the 4th quarter worth $13,328,000. Institutional investors and hedge funds own 58.58% of the company's stock.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the sale, the chief financial officer now owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is owned by corporate insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.